by Truveta staff | Apr 4, 2024 | Data
US spending on medical devices and in-vitro diagnostics totals more than $199 billion a year, with most of the costs associated with clinical development. Label expansion provides a pathway for recouping costs associated with the device development process by...
by Truveta staff | Apr 2, 2024 | Data
A common misconception is that drugs and devices must gain explicit approval from the FDA for each specific use before healthcare providers can employ them. However, a practice known as off-label use challenges this notion, revealing a broader landscape of treatment...
by Truveta staff | Feb 22, 2024 | Data, Technology
The National Academy of Medicine has estimated that less than half of all medical care in the US is supported by adequate evidence of effectiveness. The proliferation of treatment options in some disease states and the rising costs of many of those treatments have...
by Truveta staff | Jan 31, 2024 | Data
Clinical trials and registries have traditionally been the gold standard for high-quality healthcare data, offering complete longitudinal records across data domains in a clean, analysis-ready format. However, achieving this level of quality involves significant...
by Truveta staff | Nov 21, 2023 | Data
ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
by Truveta staff | Nov 1, 2023 | Data
October was a whirlwind month for Truveta, marked by participation in various conferences across the United States. In the span of less than 10 days, Truveta experts and customers presented at four different events, showcasing how Truveta Data is being used to enable...
